Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
13.68
Nov 17 • 3:59 PM ET Dollar change+0.13 Percentage change(0.96%)
Aftermarket Close
13.68
Aftermarket • 7:30 PM ET Dollar change0.00 Percentage change(0.00%)
Index
RUT
Market Cap
176.61M
Enterprise Value
158.09M
Income
-23.51M
Sales
10.01M
Book/sh
2.46
Cash/sh
2.16
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
121
IPO
Mar 20, 2014
P/E
-
Forward P/E
-
PEG
-
P/S
17.64
P/B
5.56
P/C
6.34
P/FCF
-
EV/EBITDA
-
EV/Sales
15.79
Quick Ratio
1.99
Current Ratio
2.23
Debt/Eq
0.29
LT Debt/Eq
0.26
Option/Short
Yes / Yes
EPS (ttm)
-1.82
EPS next Y
-2.16
EPS next Q
-0.59
EPS this Y
5.09%
EPS next Y
-8.34%
EPS next 5Y
10.46%
EPS past 3/5Y
18.87% 2.36%
Sales past 3/5Y
-13.82% -4.87%
EPS Y/Y TTM
3.91%
Sales Y/Y TTM
-52.19%
EPS Q/Q
-91.90%
Sales Q/Q
-34.19%
Insider Own
25.52%
Insider Trans
0.12%
Inst Own
57.79%
Inst Trans
-0.54%
ROA
-29.41%
ROE
-57.39%
ROIC
-58.65%
Gross Margin
19.54%
Oper. Margin
-342.19%
Profit Margin
-234.98%
SMA20
3.09%
SMA50
3.54%
SMA200
-8.79%
Trades
Shs Outstand
12.91M
Shs Float
9.62M
52W High
19.70 -30.56%
52W Low
11.80 15.93%
Volatility
5.81% 5.28%
ATR (14)
0.69
RSI (14)
53.79
Beta
0.03
Rel Volume
1.32
Avg Volume
118.64K
Volume
156,583
Perf Week
-3.05%
Perf Month
7.72%
Perf Quarter
0.66%
Perf Half Y
-18.01%
Perf YTD
-25.89%
Perf Year
-25.57%
Perf 3Y
64.23%
Perf 5Y
-36.96%
Perf 10Y
-65.86%
Prev Close
13.55
Price
13.68
Change %
0.96%
Consensus
Strong Buy
Avg. Price Target
$29.67
Implied Upside
+116.9%
Analysts7incl. previous ratings
Rating Distribution7 Buy · 0 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Jun 02, 2025Resumed
OPY logoOOppenheimer
Outperform$34+148.5%
May 02, 2025Initiated
AAlliance Global Partners
Buy$25+82.7%
Feb 28, 2025Initiated
CCraig Hallum
Buy$39+185.1%
Jul 16, 2024Reiterated
MMaxim Group
Buy$25 → $30+119.3%
Dec 22, 2022Initiated
MMaxim Group
Buy$11-19.6%
Jul 18, 2022Resumed
OPY logoOOppenheimer
Outperform$7-48.8%
Sep 23, 2020Initiated
BBTIG Research
Buy$6-56.1%
Nov 28, 2016Initiated
AAegis Capital
Buy$11-19.6%
Aug 17, 2016Initiated
WFC logoWWells Fargo
Outperform
Apr 16, 2014Initiated
OPY logoOOppenheimer
Outperform$25+82.7%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Rubinstein SamuelDirectorSep 01 '26Buy12.625256,626525Sep 02 04:02 PM
Rubinstein SamuelDirectorSep 01 '26Sale12.725256,6780Sep 02 04:02 PM
Hess ShmuelCOO & Chief Commercial OfficerAug 27 '26Sale12.923,95851,1490Aug 28 04:02 PM
Hess ShmuelCOO & Chief Commercial OfficerAug 26 '26Sale13.001,86524,2450Aug 28 04:02 PM
Shmulik HessOfficerAug 27 '26Proposed Sale12.703,95850,267Aug 28 06:36 AM
SHAMIR NACHUMDirectorJun 03 '26Buy14.006,00083,99655,815Jun 04 04:05 PM
Fox David MortonDirectorJun 01 '26Buy14.113,53749,90122,283Jun 02 07:30 AM
Rubinstein SamuelDirectorMay 29 '26Buy14.331502,1502,993Jun 01 07:00 AM
Hess ShmuelOfficerDec 02 '25Proposed Sale17.213,69363,557Dec 03 07:44 AM
MediWound Ltd. is a biopharmaceutical company, which engages in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Its product NexoBrid, is an orphan biologic for eschar removal in severe burns. The company was founded by Lior Rosenberg and Marian Gorecki in January 2000 and is headquartered in Yavne, Israel.
Chief Executive OfficerMr. Ofer Gonen B.Sc.
Chief Financial OfficerMs. Hani Luxenburg
COO & Chief Commercial OfficerDr. Shmulik Hess Ph.D.
Executive VPMr. Yaron Meyer Adv.
Ph.D.Dr. Ety Klinger MBA